Prognia
Drug Database
🇪🇺EU · EMAWithdrawnATC: H05BA01

Forcaltonin(recombinant salmon calcitonin)

Hypercalcemia;Osteitis Deformans;Bone Resorption

Marketing Authorisation Holder: Unigene UK Ltd.

EMA Authorisation: 11/01/1999

INN: recombinant salmon calcitonin

Indication

Calcitonin is indicated for: Prevention of acute bone loss due to sudden immobilisation such as in patients with recent osteoporotic fractures Paget's disease Hypercalcaemia of malignancy

Official EMA Resources

View on EMA (ema.europa.eu)

AI Drug & Interaction Analysis

Free account required

Ask Prognia AI about Forcaltonin — dosing recommendations, drug interactions, and current guideline evidence from ESC, EMA, NICE and more.

Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.